Open AccessAdvances in the management of esophageal cancer
Author(s) -
Bruce D. Minsky
Publication year - 2015
Publication title -
marmara medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.112
H-Index - 11
ISSN - 1309-9469
DOI - 10.5472/mmj.10059
Subject(s) - medicine , esophageal cancer , general surgery , cancer , intensive care medicine
The management of clinical stage III and IVa esophageal cancer has evolved in the past 2 decades. Based on the Cross trial, neoadjuvant chemoradiation, followed by surgical resection has become standard. For medically inoperable, definitive chemoradiation is most commonly used. The standard radiation dose is 50.4 Gy although trials of doseescalation are ongoing. At the current time, there are no definitive biomarkers to predict response. Keywords: Esophageal cancer, Radiation therapy, Chemotherapy, Dose-escalation
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom